BioDlink International Company Limited

BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features several key product candidates, including TAB008, TOZ309, TAA013, TAE020, TAB 014, and TAC020. The company was founded on December 4, 2009, and its primary base of operations is situated in Suzhou, China.

行业

Biotechnology

部门

Healthcare

总部

CN

首席执行官

Shan Fu

上市以来

2019年11月8日

雇员

596